For investors hunting exposure to the surge in neuroscience drug development, the obvious candidates are the biotech companies chasing a therapy. IXICO plc, a modestly sized business on AIM, offers a different angle: it sells the imaging analytics and trial-management technology that pharmaceutical sponsors use to measure whether their candidate drugs are working on the brain. Revenue tied to research activity, without the binary risk of a single clinical read-out.

The Quick Version

  • IXICO is an AIM-listed (IXI) neuroimaging analytics and services provider to pharma and biotech, not a drug developer.
  • FY2025 revenue rose 13% to £6.5m with the EBITDA loss narrowing to £1.3m; H1 FY2026 revenue grew 23% to £3.9m.
  • The order book reached £18.1m at 31 March 2026, up 38% year on year, giving strong forward revenue visibility.
  • A £10m equity raise completed in April 2026 (£9.4m net) is intended to help scale the AI platform and strategy.
  • Reliance on trial funding cycles was underlined by reported Huntington's disease trial cancellations, though guidance was maintained.

What IXICO Actually Does

When a pharmaceutical sponsor tests a candidate treatment for a condition like Alzheimer's, it needs standardised brain scans collected consistently across many sites, then analysed to extract measurable biomarkers of disease progression or drug effect. IXICO manages that process end to end: recruiting and qualifying imaging sites, collecting and quality-controlling scans, applying analytical algorithms, and delivering the resulting data to the sponsor. It's a technology-enabled services business, not a drug developer — fortunes track the volume and timing of clinical-trial contracts rather than the success of any particular therapy.

The AI Platform

IXICO markets a proprietary, cloud-based platform (the IXI Platform, version 10 deployed in H1 FY2026, delivering faster upload and analysis speeds) applying machine-learning and algorithmic techniques to convert raw scans into precise, reproducible measurements. Coverage spans Alzheimer's, Huntington's and Parkinson's disease imaging, with signalled work on vascular, neuromelanin and inflammation-related biomarkers.

The Numbers: Growing Order Book, Narrowing Losses

For the year ended 30 September 2025, revenue was £6.5m, up 13%, with the EBITDA loss narrowing to £1.3m from £1.7m and gross margin improving to 49%. The company ended the year debt-free with cash of £3.5m, up from £1.8m.

H1 FY2026 (to 31 March 2026) continued the trajectory: revenue rose 23% to £3.9m, gross margin improved to 53%, and the EBITDA loss narrowed to £0.5m from £0.7m. The order book reached £18.1m at 31 March 2026, up 38% year-on-year and 31% above the September 2025 year-end figure — an important forward-visibility signal, though conversion depends on trial timelines outside the company's control. An April 2026 equity raise brought in £10m gross (£9.4m net), completing after the March 2026 period-end cash figure.

The Medidata Partnership and US Push

IXICO's interim statement highlighted a partnership with Medidata (Dassault Systèmes) and the appointment of a US-based Chief Commercial Officer, part of an effort to deepen North American commercial presence. The company also described expanding operational imaging-site coverage into US and Asian time zones.

The Market and the Competition

Third-party research has estimated the broader clinical-trial imaging market at roughly $1.3bn in 2023, projected to reach around $1.9bn by 2028. IXICO competes with far larger contract-research organisations (ICON, Medpace) and specialist imaging providers (the BioClinica/Clario lineage, Invicro, Resonance Health, Perspectum). IXICO's argued edge is depth of focus — concentration on neuroscience imaging and a track record in complex indications like Huntington's disease.

Risks Worth Weighing

Client and programme concentration is notable — reported Huntington's disease trial cancellations illustrate how the loss or delay of individual trials can affect anticipated work, even where overall guidance is maintained. Revenue is inherently cyclical and dependent on pharma and biotech research budgets. As a small-cap that remains loss-making at the EBITDA level and has recently raised equity, IXICO carries financing and dilution risk. Competition from far larger organisations could pressure pricing and win rates.

What to Watch Next

Further contract wins that extend the order book and broaden the client base, particularly in Alzheimer's disease. Demonstrable commercial traction from the Medidata partnership. Tangible returns on the North American commercial investment. A clear move towards EBITDA breakeven and eventual cash generation.